Cypress Point Wealth Management LLC Makes New $744,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

Cypress Point Wealth Management LLC acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,200 shares of the biotechnology company’s stock, valued at approximately $744,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Arrowhead Pharmaceuticals by 3.3% in the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after purchasing an additional 510,798 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 2.8% in the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock worth $375,941,000 after purchasing an additional 300,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after purchasing an additional 2,017,489 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Arrowhead Pharmaceuticals by 34.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after purchasing an additional 447,456 shares in the last quarter. Finally, Baker BROS. Advisors LP boosted its stake in Arrowhead Pharmaceuticals by 77.9% in the third quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company’s stock worth $57,625,000 after purchasing an additional 731,588 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Activity

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of the stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the sale, the chief financial officer owned 162,905 shares of the company’s stock, valued at $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 33,095 shares of company stock worth $2,326,228 in the last three months. Insiders own 3.60% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of recent analyst reports. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. B. Riley Financial boosted their price objective on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Piper Sandler reissued an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Morgan Stanley raised Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $78.00 to $100.00 in a research note on Tuesday, April 21st. Finally, The Goldman Sachs Group upped their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $84.20.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $74.81 on Monday. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $12.44 and a 1-year high of $76.76. The business’s 50-day moving average price is $63.47 and its two-hundred day moving average price is $59.52. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $10.48 billion, a price-to-earnings ratio of 48.90 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The company had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. During the same period in the previous year, the company posted ($1.39) EPS. The company’s quarterly revenue was up 10461.3% compared to the same quarter last year. On average, equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.